B of A Securities has continued its coverage of Krystal Biotech (NASDAQ:KRYS) with a Buy recommendation, according to Fintel’s report dated May 25, 2023.
The average one-year price target for Krystal Biotech, as of May 11, 2023, is $115.52, down by 1.60% compared to its latest closing price of $117.39. The price forecasts for the company range from $101.00 to $141.75.
For the projected annual revenue, Krystal Biotech is estimated to have $42 million. The projected annual non-GAAP EPS is -4.84.
As of the last quarter, there are 373 funds or institutions who reported positions in Krystal Biotech, an increase of 18 owners or 5.07%. The average portfolio weight of all funds dedicated to KRYS is 0.23%, which is a decrease of 3.00%. The total shares that institutions own have decreased by 1.69% to 23,129K shares within the last three months. KRYS’s put/call ratio is at 0.52, indicating a bullish outlook.
Shareholders of Krystal Biotech
In the Biotechnology Portfolio (FBIOX), there are 2,098K shares, representing 7.62% of KRYS’s ownership. In the previous filing, the firm reported to own 2,106K shares, representing a decrease of 0.39% and an increase in its portfolio allocation on KRYS by 12.95% over the last quarter. Redmile Group owns 1,913K shares, representing 6.95% ownership of KRYS. In their prior filing, the firm reported having owned 1,897K shares, representing an increase of 0.87% on its portfolio allocation in KRYS by 8.14% over the last quarter. Avoro Capital Advisors owns 1,750K shares, representing 6.36% ownership of the company. In a prior filing, the firm owned 1,410K shares representing an increase of 19.43% on its portfolio allocation in KRYS by 24.43% over the last quarter. Lord, Abbett & Co owns 961K shares representing 3.49% ownership of the company. In a previous filing, the firm owned 1,278K shares, representing a decrease of 32.96% on its portfolio allocation in KRYS by 23.37% over the last quarter. Frazier Life Sciences Management owns 945K shares, representing 3.43% ownership of the company. In a prior filing, the firm has owned 1,000K shares, representing a decrease of 5.75%. However, the firm has increased its portfolio allocation in KRYS by 111,194.68% over the last quarter.
Krystal Biotech, a pivotal-stage gene therapy company, is leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases.
You can check Fintel’s leaderboard of companies with the largest price target upside. For more information on this company, check key filings.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
